多西紫杉醇联合顺铂治疗晚期非小细胞肺癌临床观察

Combination chemotherapy of docetaxel and cisplatin in treatment of advanced non-small-cell lung cancer

目的:观察多西紫杉醇每周疗法联合顺铂治疗晚期非小细胞肺癌临床疗效及毒副反应。方法:多西紫杉醇每周20～30mg/m2(中位剂量每周24.5mg/m2)静脉滴注,连用6周休息2周,并于第1～3天、22～24天分别给予顺铂每天25mg/m2静脉滴注,用多西紫杉醇前24h口服地塞米松8mg,2次/天,连服3天。所有患者均接受8周以上的化疗。结果:34例可评价疗效,部分缓解14例,稳定16例,进展4例,有效率41.2%。中位生存期11.6个月,1年生存率48%。毒性反应主要为骨髓抑制、腹泻、肌肉痛、恶心、呕吐、肝功能损害和皮疹。大部分患者为1～2度反应。经常规预防用药后未观察到过敏反应、水肿等。结论:多西紫杉醇每周疗法联合顺铂治疗晚期非小细胞肺癌疗效好,毒副反应轻,耐受性好,值得临床推荐应用。

Objective： To investigate the therapeutic efficacy and toxicity of combination chemotherapy of weekly docetaxel and cisplatin in treatment of advanced non-small-cell lung cancer（NSCLC）. Methods： All the patients received the following regimen： docetaxel 20- 30 mg/m^2 （median dose 24.5 mg/m^2 per week） intravenous infusion per week for 6 weeks, clsplatln 25 mg/m^2 intravenous infusion on day 1, 2, 3 and on day 22, 23, 24 before docetaxel infusion. The patients were premedicated with dexamethasone 8 mg twice for 3 days. All the patients received chemotherapy for more than 8 weeks. Results： The effect was assessed in34 cases. Among them, PR was found in 14 cases（41.2%）,SD in 16 cases and PD in 4 cases. The overall response rate was 41.2%. The median survival time was 11. 6 months and 1 year survival rate was 48%. The main toxicity profile was myelosuppression, diarrhea, muscle pain, nausea/vomlting, heptic function damage and rash. Most adverse effects were classified as grade 1 or grade 2. No allergic reaction or liqual retention was observed after preservation. Conclusions：The combination chemotherapy of weekly docetaxel and cisplatin is effective for treatment of advanced NSCLC with slight toxicity reactions.